After that, patients were monitored for diarrhea and vomiting during (4 to 5 hours) and after (12 hours) UROD.
In another Canadian study, patients submitted to moderately emetogenic chemotherapy were monitored for nausea and vomiting and a modified version of the EORTC QLQC-30 questionnaire was administered before chemotherapy and on day 2 and day 6 to assess the impact nausea and vomiting had on quality of life of the patients [ 16].
In addition, the dogs were monitored for swelling, itching, and vomiting, which are the most common signs of hypersensitivity in this species.
Patients were monitored for any side effects of nausea, vomiting, bradycardia, hypotension, and reduced SpO2 (<93%).
Nausea and vomiting were monitored for occurrence and duration.
In addition, the patient should be carefully monitored for aripiprazole-related adverse reactions, such as shaking, vomiting or confusion and alter the dose if such effects are observed.
Hemodynamics and time to recovery were monitored for 60 min. Analgesic requirements and nausea and vomiting were observed for 24 h.
They were monitored for post-TACE complications: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic decompensation (AHD) and acute kidney injury (AKI).
Nurses also monitored for possible adverse events including symptoms potentially associated with hyponatremia (vomiting, change in level of consciousness, headache) or volume overload (edema, respiratory distress).
Patients with risk factors should be carefully monitored for clinical signs of perforation, such as abdominal pain, obstipation, fever, vomiting and leucocytosis [149].
